Source-grounded facts extracted from Evolent Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Evolent Health, Inc. shareholders approved Amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan at the 2026-06-04 meeting.
“The Company’s stockholders approved the amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, as set forth below:”
Evolent Health, Inc. shareholders approved Advisory approval of compensation of named executive officers for 2025 at the 2026-06-04 meeting.
“The Company’s stockholders approved the compensation of our named executive officers for 2025 on an advisory basis, as set forth below:”
Evolent Health, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 as set forth below:”
Evolent Health, Inc. shareholders approved Election of ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the 2027 annual meeting at the 2026-06-04 meeting.
“The Company’s stockholders elected ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below:”
Evolent Health, Inc. reported quarter ended March 31, 2026 results: revenue $496,246, net income $(26,632).
“March 31, 2026 include (dollars in thousands, except for average PMPM fees and revenue per case): For the Three Months Ended March 31, 2026 2025 Financial Results: Revenue $ 496,246 $ 483,649 Net loss attributable to common shareholders of Evolent Health, Inc. $ (26,632) $ (72,250) Net loss margin (5.4) % (14.9) % Adjusted EBITDA $ 22,067 $ 36,860 Adjusted”
Diane Holder departed as Director at Evolent Health, Inc..
“Diane Holder notified the Board of Directors (the “Board”) of Evolent Health, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 5, 2025 (the “2025 Annual Meeting”).”
Brendan Springstubb was appointed as Director at Evolent Health, Inc..
“On February 4, 2025, the Board (1) appointed Mr. Springstubb as a director”
M. Bridget Duffy resigned as Director at Evolent Health, Inc..
“On February 3, 2025, M. Bridget Duffy, MD resigned from the Board.”
Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.
“Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.”
Evolent Health, Inc. updated its 2024 guidance (initiated).
“Provides initial outlook for 2024 in line with long-term targets”
Evolent Health, Inc. reported the quarter and year ended December 31, 2023 results: revenue $556,055 thousand, $1,963,896 thousand, net income ($41,395) thousand, ($142,260) thousand.
“Evolent Announces Fourth Quarter and Full Year 2023 Results • Full year revenue of $1,963.9 million, 45% growth over 2022 • Net loss attributable to common shareholders of Evolent Health, Inc. of $(142.3) million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.